Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Taxes (2023 - 2025)

Historic Change in Taxes for Gyre Therapeutics (GYRE) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • Gyre Therapeutics' Change in Taxes rose 18710.28% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$152000.0, marking a year-over-year increase of 9370.86%. This contributed to the annual value of -$2.2 million for FY2024, which is 17212.79% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Change in Taxes is $1.5 million, which was up 18710.28% from $513000.0 recorded in Q2 2025.
  • Gyre Therapeutics' Change in Taxes' 5-year high stood at $2.5 million during Q3 2023, with a 5-year trough of -$4.2 million in Q2 2024.
  • Moreover, its 3-year median value for Change in Taxes was $513000.0 (2025), whereas its average is $56363.6.
  • Over the last 5 years, Gyre Therapeutics' Change in Taxes had its largest YoY gain of 18710.28% in 2025, and its largest YoY loss of 25924.1% in 2025.
  • Over the past 3 years, Gyre Therapeutics' Change in Taxes (Quarter) stood at -$185000.0 in 2023, then soared by 135.14% to $65000.0 in 2024, then surged by 2263.08% to $1.5 million in 2025.
  • Its Change in Taxes was $1.5 million in Q3 2025, compared to $513000.0 in Q2 2025 and -$2.3 million in Q1 2025.